Patients with RA ( n = 34 ) with moderate disease activity who were receiving stable disease-modifying antirheumatic drug therapy were randomized to drug sequence , receiving either pioglitazone 45 mg/day or matching placebo for 8 weeks , followed by a 4-week washout period and the alternative treatment for 8 weeks .